PL3423087T3 - Skojarzona terapia przeciwnowotworowa - Google Patents
Skojarzona terapia przeciwnowotworowaInfo
- Publication number
- PL3423087T3 PL3423087T3 PL17709038.8T PL17709038T PL3423087T3 PL 3423087 T3 PL3423087 T3 PL 3423087T3 PL 17709038 T PL17709038 T PL 17709038T PL 3423087 T3 PL3423087 T3 PL 3423087T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer therapy
- combination anti
- combination
- cancer
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603805.1A GB201603805D0 (en) | 2016-03-04 | 2016-03-04 | Combination |
| GBGB1610018.2A GB201610018D0 (en) | 2016-06-08 | 2016-06-08 | Combination |
| PCT/EP2017/055093 WO2017149150A1 (en) | 2016-03-04 | 2017-03-03 | Combination therapy against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3423087T3 true PL3423087T3 (pl) | 2024-05-20 |
Family
ID=58231605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17709038.8T PL3423087T3 (pl) | 2016-03-04 | 2017-03-03 | Skojarzona terapia przeciwnowotworowa |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190343940A1 (enExample) |
| EP (2) | EP3423087B1 (enExample) |
| JP (3) | JP2019507180A (enExample) |
| DK (1) | DK3423087T3 (enExample) |
| ES (1) | ES2965009T3 (enExample) |
| FI (1) | FI3423087T3 (enExample) |
| HR (1) | HRP20240052T1 (enExample) |
| HU (1) | HUE064857T2 (enExample) |
| LT (1) | LT3423087T (enExample) |
| PL (1) | PL3423087T3 (enExample) |
| PT (1) | PT3423087T (enExample) |
| SI (1) | SI3423087T1 (enExample) |
| WO (1) | WO2017149150A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| CA3001131A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| HUE064857T2 (hu) * | 2016-03-04 | 2024-04-28 | Io Biotech Aps | Kombinációs terápia a rák ellen |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| CN110546509A (zh) | 2017-04-28 | 2019-12-06 | 戊瑞治疗有限公司 | 用cd80细胞外结构域多肽进行治疗的方法 |
| SG11202000387YA (en) | 2017-08-25 | 2020-03-30 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof |
| WO2019102265A1 (en) * | 2017-11-23 | 2019-05-31 | Theraphage Inc. | Peptide displaying bacteriophage nanoparticles and related compositions and methods |
| EP3713645A1 (en) * | 2017-11-24 | 2020-09-30 | IO Biotech APS | Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc) |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| AU2019361923B2 (en) | 2018-10-15 | 2026-07-09 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| GB201818576D0 (en) * | 2018-11-14 | 2018-12-26 | Io Biotech Aps | Arginase 2 polypeptides |
| AU2020224137B2 (en) | 2019-02-22 | 2026-01-08 | Five Prime Therapeutics, Inc. | CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors |
| MX2021013272A (es) | 2019-05-03 | 2021-11-17 | Five Prime Therapeutics Inc | Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80. |
| KR102653960B1 (ko) * | 2020-07-23 | 2024-04-03 | 의료법인 성광의료재단 | 암 치료를 위한 면역체크포인트 억제제의 병용 요법 |
| BR112023017582A2 (pt) | 2021-03-05 | 2023-12-05 | Univ Basel | Composições para o tratamento de doenças ou condições associadas ao ebv |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| GB202103673D0 (en) * | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| CN117642432A (zh) * | 2021-05-17 | 2024-03-01 | 威斯康星校友研究基金会 | 用于诱导免疫耐受的合成蛋白 |
| EP4479085A1 (en) * | 2022-02-18 | 2024-12-25 | ModernaTX, Inc. | Mrnas encoding checkpoint cancer vaccines and uses thereof |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| WO2026008017A1 (en) * | 2024-07-03 | 2026-01-08 | Everest Medicines (China) Co., Ltd. | Cancer vaccines and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US20100055111A1 (en) * | 2007-02-14 | 2010-03-04 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| DK2280721T3 (da) * | 2008-04-17 | 2018-01-29 | Io Biotech Aps | Indoleamin-2, 3-dioxygenasebaseret immunterapi |
| ES2918580T3 (es) * | 2011-10-17 | 2022-07-19 | Io Biotech Aps | Inmunoterapia basada en PD-L1 |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| PH12020550847A1 (en) * | 2014-02-04 | 2022-05-11 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| ES2715018T3 (es) * | 2014-05-30 | 2019-05-31 | Ventana Med Syst Inc | Ensayo múltiple para puntuar mejor los tejidos tumorales teñidos para PD-L1 |
| HUE064857T2 (hu) * | 2016-03-04 | 2024-04-28 | Io Biotech Aps | Kombinációs terápia a rák ellen |
-
2017
- 2017-03-03 HU HUE17709038A patent/HUE064857T2/hu unknown
- 2017-03-03 US US16/081,778 patent/US20190343940A1/en not_active Abandoned
- 2017-03-03 WO PCT/EP2017/055093 patent/WO2017149150A1/en not_active Ceased
- 2017-03-03 PT PT177090388T patent/PT3423087T/pt unknown
- 2017-03-03 SI SI201731444T patent/SI3423087T1/sl unknown
- 2017-03-03 PL PL17709038.8T patent/PL3423087T3/pl unknown
- 2017-03-03 EP EP17709038.8A patent/EP3423087B1/en active Active
- 2017-03-03 EP EP23202447.1A patent/EP4316517A3/en active Pending
- 2017-03-03 DK DK17709038.8T patent/DK3423087T3/da active
- 2017-03-03 ES ES17709038T patent/ES2965009T3/es active Active
- 2017-03-03 FI FIEP17709038.8T patent/FI3423087T3/fi active
- 2017-03-03 JP JP2018546596A patent/JP2019507180A/ja active Pending
- 2017-03-03 HR HRP20240052TT patent/HRP20240052T1/hr unknown
- 2017-03-03 LT LTEPPCT/EP2017/055093T patent/LT3423087T/lt unknown
-
2021
- 2021-09-07 US US17/468,263 patent/US20220257741A1/en not_active Abandoned
-
2022
- 2022-02-25 JP JP2022027569A patent/JP7417645B2/ja active Active
-
2024
- 2024-01-05 JP JP2024000506A patent/JP7785817B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| LT3423087T (lt) | 2024-01-25 |
| US20190343940A1 (en) | 2019-11-14 |
| EP3423087A1 (en) | 2019-01-09 |
| PT3423087T (pt) | 2023-12-28 |
| ES2965009T3 (es) | 2024-04-10 |
| HRP20240052T1 (hr) | 2024-03-29 |
| FI3423087T3 (fi) | 2023-12-15 |
| WO2017149150A1 (en) | 2017-09-08 |
| JP2024045180A (ja) | 2024-04-02 |
| JP7417645B2 (ja) | 2024-01-18 |
| EP3423087B1 (en) | 2023-11-15 |
| HUE064857T2 (hu) | 2024-04-28 |
| EP4316517A2 (en) | 2024-02-07 |
| JP2019507180A (ja) | 2019-03-14 |
| US20220257741A1 (en) | 2022-08-18 |
| DK3423087T3 (da) | 2023-12-18 |
| SI3423087T1 (sl) | 2024-03-29 |
| EP4316517A3 (en) | 2024-05-29 |
| JP7785817B2 (ja) | 2025-12-15 |
| JP2022068348A (ja) | 2022-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3463464A4 (en) | ASSOCIATION TREATMENT | |
| EP3368656A4 (en) | TARGETED CANCER THERAPY | |
| EP3563835A4 (en) | NEW EXOSOME-BASED ANTI-CANCER AGENT | |
| DK3328880T3 (da) | Terapeutiske midler | |
| EP3291824A4 (en) | ANTIMICROBIAL THERAPY | |
| DK3240801T3 (da) | Kombinationstumorimmunterapi | |
| EP3445380C0 (en) | BACTERIOTHERAPY | |
| EP3499651A4 (en) | Connector | |
| PL3622953T3 (pl) | Leczenie skojarzone nowotworu | |
| EP3424940A4 (en) | Radiolabeled drug | |
| EP3413927A4 (en) | CANCER THERAPY | |
| EP3297102A4 (en) | Connector | |
| EP3345041A4 (en) | Dual-direction collimator | |
| IL260347A (en) | Therapeutic anti-cd9 antibody | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| IL262851A (en) | Combination prime: boost therapy | |
| DK3393478T3 (da) | Kombinationsterapi | |
| EP3246047C0 (en) | COMBINATION MEDICATION | |
| EP3437644A4 (en) | MEDICINE | |
| EP3541931A4 (en) | COMBINED FRACTAL TREATMENT | |
| EP3256115A4 (en) | COMBINATION CANCER THERAPY | |
| EP3527216A4 (en) | MEDICINE | |
| DK3432901T3 (da) | Sekventiel antikræftbehandling | |
| EP3334447A4 (en) | CCK2R-drug conjugates |